Diagnostic lab, molecular, and genomics claim denials rose 40% to 11.2% in 2025, driven by insurer automation and more prior authorization rejections, according to XiFin’s 2026 Payor Denial Impact Report.
CMS has released preliminary 2027 CLFS rates, with data showing weighted median payment cuts for over 1,100 test codes; annual reductions are capped at 15% from 2027 to 2029 under current policy.
A peer-reviewed study found that Olink proximity extension assay technology correlates with ELISA for measuring endothelin-1 in coronary artery plasma, supporting its use for high-throughput proteomics in clinical research.
Werfen has launched a web-based platform designed to centralize autoimmune testing data, automate workflows, and integrate with laboratory information systems for high-volume clinical labs.
A study found that Quest Diagnostics’ Haystack MRD ctDNA test detected colorectal cancer recurrence with up to 100% specificity, outperforming CEA testing in DYNAMIC trial patient specimens.
